Unknown PHASE4 INTERVENTIONAL 3-arm NCT01906788

The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy

THE OPTIMAL TIMING OF PRIMAQUINE TO PREVENT MALARIA TRANSMISSION AFTER ARTEMISININ-COMBINATION THERAPY

Sponsor: Ifakara Health Institute

Interventions Artemether Lumefantrine Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0 Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2

Updated 6 times since 2017 Last updated: Jul 23, 2013 Started: May 31, 2013 Primary completion: Oct 31, 2013 Completion: Oct 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Malaria Transmission and is currently ongoing. Ifakara Health Institute leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ifakara Health Institute
Kilimanjaro Clinical Research Institute
London School of Hygiene and Tropical Medicine

Data source: Kilimanjaro Clinical Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bagamoyo, Tanzania